What is CODAGENIX?
CODAGENIX is a biotechnology firm leveraging a proprietary synthetic biology approach that combines codon deoptimization with live-attenuated viruses. This innovative technology is designed to create transformative vaccines and therapeutics for global health challenges. By precisely editing viral genomes, Codagenix aims to develop solutions that offer the robust immunity of live-attenuated viruses while ensuring enhanced safety, accelerated development timelines, and scalable production. The company's focus on addressing infectious diseases positions it as a key player in the fight against significant global health threats.
How much funding has CODAGENIX raised?
CODAGENIX has raised a total of $49M across 5 funding rounds:
Multiple Rounds
$2M
Series A
$2M
Series B
$45M
Unspecified (2014): $100K with participation from Accelerate Long Island
Grant (2014): $222K led by National Institutes of Health
Angel/Seed (2014): $1.7M supported by National Institutes of Health and State of New York - Empire State Development
Series A (2015): $2M featuring Topspin Partners
Series B (2023): $45M backed by Serum Institute of India Pvt. Ltd., Euclidean Capital, and Adjuvant Capital
Key Investors in CODAGENIX
Serum Institute of India Pvt. Ltd.
Serum Institute of India Pvt. Ltd. is a prominent Indian manufacturer of immunobiological drugs, particularly known for its extensive vaccine production capabilities, contributing significantly to global public health initiatives.
Adjuvant Capital
Adjuvant Capital is a venture capital firm dedicated to financing innovative life science technologies that address high-burden public health challenges, with a focus on infectious diseases and maternal/child health.
Topspin Partners
Topspin Partners is a private equity firm that specializes in growing branded consumer products and services companies, providing strategic guidance and capital access to facilitate expansion.
What's next for CODAGENIX?
The recent major enterprise-level funding and strategic investment indicate that CODAGENIX is poised for significant expansion and acceleration of its research and development initiatives. This capital infusion is expected to fuel the advancement of its pipeline, potentially leading to the clinical testing and commercialization of its novel vaccine and therapeutic candidates. The company's commitment to tackling infectious diseases, coupled with its advanced synthetic biology platform, suggests a strategic focus on addressing unmet medical needs and strengthening global health security. CODAGENIX is likely to invest in expanding its operational capacity, forging strategic partnerships, and further building its scientific team to capitalize on its technological advantages.
See full CODAGENIX company page
